Sign in Subscribe

combination

A collection of 67 issues

FGFR inhibition enhances immune checkpoint blockade in preclinical models

Skip to content The CRC Digest ◇ RESEARCH FGFR inhibition enhances immune checkpoint blockade in preclinical models Combining FGFR pathway inhibition with PD-1 blockade reduced T cell exhaustion and promoted antitumor macrophage activity in microsatellite stable colorectal cancer models, with TCGA data showing high FGFR3 expression correlates with worse prognosis. (BMC

Fruquintinib plus TAS-102 shows activity in heavily pretreated metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Fruquintinib plus TAS-102 shows activity in heavily pretreated metastatic colorectal cancer A phase II trial of 50 patients who had failed at least two prior therapies found median progression-free survival of 6.07 months and overall survival of 14.10 months, with

ATOMIC trial shows 86% three-year disease-free survival with atezolizumab combination

Skip to content The CRC Digest ◆ TRIAL DATA ATOMIC trial shows 86% three-year disease-free survival with atezolizumab combination At a median follow-up of 40.9 months in the ATOMIC trial, the 3-year disease-free survival rate was 86.3% in patients receiving atezolizumab plus mFOLFOX6 compared with 76.2% in those

FDA approves atezolizumab plus chemotherapy for Stage III dMMR colon cancer

Skip to content The CRC Digest ● REGULATORY FDA approves atezolizumab plus chemotherapy for Stage III dMMR colon cancer The FDA approved atezolizumab in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of adult and pediatric patients two years and older with Stage III mismatch repair deficient colon cancer. Efficacy

Pathologic complete response achieved with tislelizumab, cetuximab, and dabrafenib in BRAF V600E-mutant metastatic colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Pathologic complete response achieved with tislelizumab, cetuximab, and dabrafenib in BRAF V600E-mutant metastatic colorectal cancer A case report describes a 26-year-old woman with microsatellite-stable, BRAF V600E-mutant stage IVC disease who achieved complete remission with first-line immunotherapy and targeted therapy combination, without cytotoxic chemotherapy.

Blocking PLA1A enzyme may enhance chemoimmunotherapy by reducing immunosuppressive macrophages

Skip to content The CRC Digest ◇ RESEARCH Blocking PLA1A enzyme may enhance chemoimmunotherapy by reducing immunosuppressive macrophages Single-cell RNA sequencing of paired samples before and after neoadjuvant chemotherapy revealed that non-responders had increased M2-like macrophage infiltration linked to elevated PLA1A. (Cancer Res) This content is informational only and does not

Phase II trial compares sequencing of regorafenib and anti-EGFR therapy in refractory metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase II trial compares sequencing of regorafenib and anti-EGFR therapy in refractory metastatic colorectal cancer The REVERCE II trial randomized patients with RAS wild-type metastatic colorectal cancer to receive either regorafenib followed by anti-EGFR therapy or the reverse sequence, evaluating overall survival

Radiation plus dual checkpoint blockade evaluated in MSS metastatic disease

Skip to content The CRC Digest ▸ TREATMENT Radiation plus dual checkpoint blockade evaluated in MSS metastatic disease A multi-institution phase II study enrolled patients with microsatellite stable metastatic colorectal cancer previously treated with oxaliplatin, 5-fluorouracil, and irinotecan to receive combined radiation therapy and nivolumab/ipilimumab, with the primary endpoint being

Pembrolizumab plus HER2-targeted ADC tested in pretreated HER2-positive mCRC

Skip to content The CRC Digest ▸ TREATMENT Pembrolizumab plus HER2-targeted ADC tested in pretreated HER2-positive mCRC A multicenter phase II study evaluated pembrolizumab combined with disitamab vedotin, an anti-HER2 antibody-drug conjugate, in patients with microsatellite stable, HER2-positive metastatic colorectal cancer who had received at least two prior lines of therapy.

OSERO Study Examines Treatment Sequencing of Regorafenib and FTD/TPI in Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT OSERO Study Examines Treatment Sequencing of Regorafenib and FTD/TPI in Metastatic CRC The OSERO study was a prospective observational study in patients with metastatic colorectal cancer scheduled for later-line treatment with regorafenib or trifluridine/tipiracil (FTD/TPI), with or without bevacizumab. (British